Sponsor Interviews

Galien medal grey
BCG logo

Being Part of the Innovation Agenda

The Galien Foundation interviewed Priya Chandran, Managing Director and Senior Partner at Boston Consulting Group (BCG) about BCG’s ongoing partnership with the Galien Foundation and her perspective on the value of the Prix Galien.

What motivates BCG’s sponsorship of the Galien process?

The Galien Forum and Prix Galien USA Ceremony are events where the best and the brightest show up. Our clients come here, and I know that their senior members feel personally engaged in the process.From a pure business perspective, it makes sense for us to support something that our most senior clients value and participate in.

Beyond that, we also strongly identify with the Galien Foundation mission—to drive, recognize, and honor innovation. I have worked in R&D all my life, and it’s such a hard job. R&D carries such a high failure rate, requiring such endurance and perseverance. The fact that the Galien process promotes and recognizes that is critical.

What role does BCG play in health innovation and the life sciences?

BCG is known as a place that is innovative, has big ideas, and drives positive disruption. We’ve come up with a lot of the big ideas in healthcare. For us, being part of an innovation agenda has always been a big deal for us.

Healthcare is one of BCG’s three largest practice areas and has always been a critical priority. We have extensive work in all aspects of healthcare, from pharmaceuticals, to med tech, to payers and providers, to global health. From a societal perspective, we think healthcare presents the most critical sets of problems and opportunities.

Internally, health issues mean a lot to our people. For example, many of my fellow partners attended the Galien events with me. Participating in person energizes us.

What is the value of the awards themselves – the Prix Galien?

I think that the recognition is extraordinarily important. It’s a recognition from peers for innovation that has a major impact, so I would guess that as a scientist it’s probably a pretty energizing feeling.

The Prix Galien are clearly established as awards that are worth getting – they stand out among the numerous prizes that exist these days. Everybody – the crème de la crème – shows up in person in honor of these awards. So clearly there is something about the the community that Prix Galien has created.

Galien medal red

President Research and Development Solutions, IQVIA


Prix Galien is always a special event for IQVIA. Not only because we are so strongly aligned with the Galien Foundation’s vision to improve the human condition, but also because Prix Galien offers an important moment for the industry at large to, for one night, pause its relentless pursuit of innovation and marvel at what we have achieved. And in the past year, we achieved some incredible successes.

From discoveries to mitigate the pandemic’s most devastating blows to important advances across a broad range of therapeutic areas, the scientific community has given the world much-needed pathways to a healthier world. Yes, it has been a year of challenges. But it has also been a year of triumph, of breakthroughs, of communities of researchers pushing through boundaries and achieving what many said could never be done. I offer my sincere thanks to everyone here today and to all our colleagues around the world who brought these achievements to life.

Now, our industry stands at the beginning of a new era — a better era. Crises are ripe for innovation and change, and COVID-19 has driven all of us toward approaches we have long known are the future of clinical development. As a result, research improved in ways that will continue to serve us long after the pandemic. From increased transparency to the use of novel technology to accelerate engagement and reduce patient burden, there’s no doubt that we are coming out of 2021 a better, more resilient industry than we were pre-pandemic.

Our next era is also marked by a deep commitment to proactively tackle the diversity and inclusion challenges in clinical trials. The disproportionate impact of COVID-19 on minority populations left no doubt that we urgently need meaningful action on this front, and I’m proud that we are rising to the challenge. Our industry is reimagining trial planning and execution at every step, linking insights on diverse demographics with action to better bring these populations into the fold.

It’s an exciting time for our industry. The biggest healthcare challenge of our lifetime has unlocked big possibilities for technology, innovation and health equity. To make the most of them, we’ll need to connect intelligence across every asset we have — including expertise, novel solutions, data and analytics — in concert to deliver previously unseen insights, enable smarter decision- making and unleash innovation. Look at where our combined scientific ingenuity brought us since the beginning of the pandemic to today. The possibilities are endless if we apply the same determination and focus on the opportunities of tomorrow.

I’d like to extend my sincere congratulations to the Galien Foundation and all of you for your important work. Let’s keep pioneering together, breaking boundaries and collaborating for a healthier world.

So many organizations across the industry are similarly meeting this moment, rising to the challenge of a new era for healthcare. Prix Galien celebrates these achievements, and I am proud that IQVIA is a partner to many of the innovators we recognize.

At the same time, I also know that none of us are in this industry for recognition. We are all driven by a relentless desire to apply science and research in ways that advance human health. The potential for our work to have a tangible impact on the lives of patients has never been more pronounced, and IQVIA is privileged to work alongside industry colleagues, including Prix Galien, that share our passion for improving the human experience.

Thank you to Prix Galien for continuing to shine a beacon on our industry’s most important efforts.
Let’s keep pushing the boundaries of what is possible and go change the world.